Multigene testing for hereditary cancer: When, why, and how Journal Article
| Author: | Offit, K. |
| Article Title: | Multigene testing for hereditary cancer: When, why, and how |
| Abstract: | Multigene testing is a complicated area, with advantages and disadvantages of testing for hereditary cancer syndromes. Currently, NCCN does not endorse routing multiplex testing outside of a research setting, and/or intensive genetic counseling regarding risks and benefits. The 2017 NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian and Colorectal provide suggestions for mutation carriers identified by panel tests. Copyright © 2017 by the National Comprehensive Cancer Network. |
| Keywords: | genetics; genetic predisposition to disease; risk factors; practice guideline; risk factor; practice guidelines as topic; tumor gene; genetic predisposition; genetic screening; genetic testing; molecular diagnosis; molecular diagnostic techniques; neoplastic syndromes, hereditary; genes, neoplasm; humans; human; hereditary tumor syndrome |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 15 |
| Issue: | 5.5 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2017-05-01 |
| Start Page: | 741 |
| End Page: | 743 |
| Language: | English |
| PUBMED: | 28515260 |
| PROVIDER: | scopus |
| DOI: | 10.6004/jnccn.2017.0089 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 April 2018 -- Source: Scopus |
